BIOMAT Database Logo BIOMAT Database Logo

Ketoconazole in vulvovaginal candidosis. 1984

A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez

UI MeSH Term Description Entries
D007654 Ketoconazole Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Nizoral,R-41400,R41,400,R41400,R 41400
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002181 Candidiasis, Vulvovaginal Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA. Moniliasis, Vulvovaginal,Vaginitis, Monilial,Candidiasis, Genital,Genital Vulvovaginal Candidiasis,Vaginal Yeast Infection,Vaginal Yeast Infections,Candidiasis, Genital Vulvovaginal,Genital Candidiasis,Infection, Vaginal Yeast,Infections, Vaginal Yeast,Monilial Vaginitis,Vulvovaginal Candidiasis,Vulvovaginal Candidiasis, Genital,Vulvovaginal Moniliasis,Yeast Infection, Vaginal,Yeast Infections, Vaginal
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez
Ketoconazole in vulvovaginal candidosis.
January 1980, Reviews of infectious diseases,
A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez
Vulvovaginal candidosis.
June 2007, Lancet (London, England),
A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez
Vulvovaginal candidosis.
July 1991, The Journal of antimicrobial chemotherapy,
A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez
Recurrent vulvovaginal candidosis.
January 1991, International journal of STD & AIDS,
A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez
Ketoconazole in experimental candidosis.
January 1980, Reviews of infectious diseases,
A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez
Vulvovaginal candidosis and oral contraceptives.
August 1974, Mykosen,
A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez
Effects of oestrogen on vulvovaginal candidosis.
January 2022, Mycoses,
A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez
Ketoconazole in experimental vaginal candidosis in rats.
November 1986, Antimicrobial agents and chemotherapy,
A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez
Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
March 2015, Mycoses,
A del Palacio-Hernanz, and F Sanz-Sanz, and A Rodriguez-Noriega, and C Gomez-Alvarez
Recurrent vulvovaginal candidosis: focus on the vulva.
November 2011, Mycoses,
Copied contents to your clipboard!